Literature DB >> 28193546

Contribution of guanine nucleotide exchange factor Vav2 to NLRP3 inflammasome activation in mouse podocytes during hyperhomocysteinemia.

Sabena M Conley1, Justine M Abais-Battad1, Xinxu Yuan1, Qinghua Zhang1, Krishna M Boini2, Pin-Lan Li3.   

Abstract

NADPH oxidase (NOX)-derived reactive oxygen species (ROS) have been demonstrated to mediate the activation of NOD-like receptor protein 3 (NLRP3) inflammasomes in podocytes in response to elevated levels of homocysteine (Hcys). However, it remains unknown how NLRP3 inflammasome activation is triggered by NOX. The present study tested whether the guanine nucleotide exchange factor Vav2 mediates Rac1-mediated NOX activation in response to elevated Hcys leading to NLRP3 inflammasome activation in podocytes and consequent glomerular injury. In a mouse model of hyperhomocysteinemia (hHcys), we found that mice with hHcys (on the FF diet) or oncoVav2 (a constitutively active form of Vav2) transfection in the kidney exhibited increased colocalization of NLRP3 with apoptosis-associated speck-like protein (ASC) or caspase-1 and elevated IL-1β levels in glomeruli, indicating the formation and activation of the NLRP3 inflammasome. This glomerular NLRP3 inflammasome activation was accompanied by podocyte dysfunction and glomerular injury, even sclerosis. Local transfection of Vav2 shRNA plasmids significantly attenuated hHcys-induced NLRP3 inflammasome activation, podocyte injury, and glomerular sclerosis. In cultured podocytes, Hcys treatment and oncoVav2 transfection were also found to increase NLRP3 inflammasome formation and activation, which were all inhibited by Vav2 shRNA. Furthermore, Vav2 shRNA prevented Hcys-induced podocyte damage as shown by restoring Hcys-impaired VEGF secretion and podocin production. This inhibitory action of Vav2 shRNA on Hcys-induced podocyte injury was associated with reduction of Rac1 activity and ROS production. These results suggest that elevated Hcys levels activate Vav2 and thereby increase NOX activity leading to ROS production, which triggers NLRP3 inflammasome activation, podocyte dysfunction and glomerular injury.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  End-stage renal disease; Hyperhomocysteinemia; Inflammatory machinery; Podocytes

Mesh:

Substances:

Year:  2017        PMID: 28193546      PMCID: PMC5423457          DOI: 10.1016/j.freeradbiomed.2017.02.027

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  45 in total

1.  Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia.

Authors:  Chun Zhang; Krishna M Boini; Min Xia; Justine M Abais; Xiang Li; Qinglian Liu; Pin-Lan Li
Journal:  Hypertension       Date:  2012-05-29       Impact factor: 10.190

Review 2.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Authors:  S J Shankland
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

3.  Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.

Authors:  Adam T Whaley-Connell; E Matthew Morris; Nathan Rehmer; J Cipporah Yaghoubian; Yongzhong Wei; Melvin R Hayden; Javad Habibi; Craig S Stump; James R Sowers
Journal:  Am J Nephrol       Date:  2007-01-05       Impact factor: 3.754

4.  The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C.

Authors:  L Norlund; A Grubb; G Fex; H Leksell; J E Nilsson; H Schenck; B Hultberg
Journal:  Clin Chem Lab Med       Date:  1998-03       Impact factor: 3.694

Review 5.  Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes.

Authors:  A G Bostom; L Lathrop
Journal:  Kidney Int       Date:  1997-07       Impact factor: 10.612

6.  Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats.

Authors:  F Yi; A Y Zhang; N Li; R W Muh; M Fillet; A-F Renert; P-L Li
Journal:  Kidney Int       Date:  2006-05-10       Impact factor: 10.612

Review 7.  The NLRP3 inflammasome in kidney disease and autoimmunity.

Authors:  Holly L Hutton; Joshua D Ooi; Stephen R Holdsworth; A Richard Kitching
Journal:  Nephrology (Carlton)       Date:  2016-09       Impact factor: 2.506

8.  The actin cytoskeleton reorganization induced by Rac1 requires the production of superoxide.

Authors:  L Moldovan; K Irani; N I Moldovan; T Finkel; P J Goldschmidt-Clermont
Journal:  Antioxid Redox Signal       Date:  1999       Impact factor: 8.401

Review 9.  Renal tubule albumin transport.

Authors:  Michael Gekle
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

Review 10.  Guanine nucleotide exchange factors: activators of Ras superfamily proteins.

Authors:  A F Overbeck; T R Brtva; A D Cox; S M Graham; S Y Huff; R Khosravi-Far; L A Quilliam; P A Solski; C J Der
Journal:  Mol Reprod Dev       Date:  1995-12       Impact factor: 2.609

View more
  10 in total

1.  Sphingolipids and Redox Signaling in Renal Regulation and Chronic Kidney Diseases.

Authors:  Owais M Bhat; Xinxu Yuan; Guangbi Li; RaMi Lee; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2018-01-09       Impact factor: 8.401

2.  Activation of the NLRP3 inflammasome by RAC1 mediates a new mechanism in diabetic nephropathy.

Authors:  Changjiang Ying; Zhongyuan Zhou; Jiao Dai; Meng Wang; Jie Xiang; Dong Sun; Xiaoyan Zhou
Journal:  Inflamm Res       Date:  2022-01-14       Impact factor: 4.575

Review 3.  Metabolic Dysfunction in the Regulation of the NLRP3 Inflammasome Activation: A Potential Target for Diabetic Nephropathy.

Authors:  Wenli Zhao; Le Zhou; Petr Novák; Xian Shi; Chuang Biao Lin; Xiao Zhu; Kai Yin
Journal:  J Diabetes Res       Date:  2022-06-09       Impact factor: 4.061

4.  Hepatitis B virus X mediates podocyte pyroptosis by regulating the ROS/NLRP3 signaling pathway in hepatitis B virus-associated glomerulonephritis.

Authors:  Yani Yu; Hui Dong; Jingyi Sun; Baoshuang Li; Yueqi Chen; Moxuan Feng; Xiaoqian Yang; Wei Jiang
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

Review 5.  Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders.

Authors:  Swarup Mitra; Avijit Banik; Sumit Saurabh; Malabika Maulik; Shailesh N Khatri
Journal:  J Neurosci       Date:  2022-01-13       Impact factor: 6.709

6.  Contribution of podocyte inflammatory exosome release to glomerular inflammation and sclerosis during hyperhomocysteinemia.

Authors:  Dandan Huang; Guangbi Li; Qinghua Zhang; Owais M Bhat; Yao Zou; Joseph K Ritter; Pin-Lan Li
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-04-14       Impact factor: 6.633

7.  Rac1 GTPase Inhibition Blocked Podocyte Injury and Glomerular Sclerosis during Hyperhomocysteinemia via Suppression of Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation.

Authors:  Qinghua Zhang; Sabena M Conley; Guangbi Li; Xinxu Yuan; Pin-Lan Li
Journal:  Kidney Blood Press Res       Date:  2019-07-02       Impact factor: 2.687

8.  Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats.

Authors:  Qiuyue Lv; Liang Le; Jiamei Xiang; Baoping Jiang; Sibao Chen; Peigen Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-17       Impact factor: 5.555

Review 9.  Involvement of Inflammasome Components in Kidney Disease.

Authors:  Ana Karina Aranda-Rivera; Anjali Srivastava; Alfredo Cruz-Gregorio; José Pedraza-Chaverri; Shrikant R Mulay; Alexandra Scholze
Journal:  Antioxidants (Basel)       Date:  2022-01-27

10.  Advanced oxidation protein products induce microglia-mediated neuroinflammation via MAPKs-NF-κB signaling pathway and pyroptosis after secondary spinal cord injury.

Authors:  Zhongyuan Liu; Xinqiang Yao; Wangsheng Jiang; Wei Li; Siyuan Zhu; Congrui Liao; Lin Zou; Ruoting Ding; Jianting Chen
Journal:  J Neuroinflammation       Date:  2020-03-20       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.